In clinical trials of new medicines, half of the subjects : GMAT Critical Reasoning (CR)
Check GMAT Club Decision Tracker for the Latest School Decision Releases http://gmatclub.com/AppTrack

 It is currently 24 Jan 2017, 14:39

### GMAT Club Daily Prep

#### Thank you for using the timer - this advanced tool can estimate your performance and suggest more practice questions. We have subscribed you to Daily Prep Questions via email.

Customized
for You

we will pick new questions that match your level based on your Timer History

Track

every week, we’ll send you an estimated GMAT score based on your performance

Practice
Pays

we will pick new questions that match your level based on your Timer History

# Events & Promotions

###### Events & Promotions in June
Open Detailed Calendar

# In clinical trials of new medicines, half of the subjects

Author Message
TAGS:

### Hide Tags

SVP
Joined: 30 Oct 2003
Posts: 1793
Location: NewJersey USA
Followers: 6

Kudos [?]: 98 [0], given: 0

In clinical trials of new medicines, half of the subjects [#permalink]

### Show Tags

31 Dec 2003, 13:40
00:00

Difficulty:

(N/A)

Question Stats:

100% (03:10) correct 0% (00:00) wrong based on 10 sessions

### HideShow timer Statistics

18. In clinical trials of new medicines, half of the subjects receive the drug being tested and half receive a physiologically inert substance ?a placebo. Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. However, this intention is frequently frustrated because ____.

Which one of the following, if true, most appropriately completes the explanation?

(A) often the subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug

(B) subjects who believe they are receiving the drug being tested often display improvements in their conditions regardless of whether what is administered to them is physiologically active or not

(C) in general, when the trial is intended to establish the experimental drug's safety rather than its effectiveness, all of the subjects are healthy

(D) when a trial runs a long time, few of the experimenters will work on it from inception to conclusion

(E) the people who are subjects for clinical trials must, by law, be volunteers and must be informed of the possibility that they will receive a placebo
If you have any questions
New!
Senior Manager
Joined: 05 May 2003
Posts: 424
Location: Aus
Followers: 2

Kudos [?]: 10 [0], given: 0

### Show Tags

31 Dec 2003, 15:15
I will go with A.
Though B seems to be close
SVP
Joined: 30 Oct 2003
Posts: 1793
Location: NewJersey USA
Followers: 6

Kudos [?]: 98 [0], given: 0

### Show Tags

31 Dec 2003, 15:39
Correct answer is A. I chose B. If you guys have time please justify your answers. Your reasoning ( right or wrong ) will definitely help me and others.
Senior Manager
Joined: 05 May 2003
Posts: 424
Location: Aus
Followers: 2

Kudos [?]: 10 [2] , given: 0

### Show Tags

31 Dec 2003, 15:57
2
KUDOS
Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested.

As per the expectation either the subjects or the experimenters should know who has been given the drug. But the experimenters come to know because of the side effects.
SVP
Joined: 30 Oct 2003
Posts: 1793
Location: NewJersey USA
Followers: 6

Kudos [?]: 98 [0], given: 0

### Show Tags

31 Dec 2003, 16:08
Hats off to you. Unbelievable reasoning. Fantastic explaination indeed.
Manager
Joined: 13 Apr 2014
Posts: 73
Followers: 2

Kudos [?]: 118 [1] , given: 196

In clinical trials of new medicines, half of the subjects receive the [#permalink]

### Show Tags

10 Dec 2014, 19:56
1
KUDOS
1
This post was
BOOKMARKED
In clinical trials of new medicines, half of the subjects receive the drug being tested and half receive a physiologically inert substance—a placebo. Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. However, this intention is frequently frustrated because______
Which one of the following, if true, most appropriately completes the explanation?
(A) often the subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug
(B) subjects who believe they are receiving the drug being tested often display improvements in their conditions regardless of whether what is administered to them is physiologically active or not
(C) in general, when the trial is intended to establish the experimental drug’s safety rather than its effectiveness, all of the subjects are healthy
(D) when a trial runs a long time, few of the experimenters will work on it from inception to conclusion
(E) the people who are subjects for clinical trials must, by law, be volunteers and must be informed of the possibility that they will receive a placebo
Senior Manager
Joined: 02 Dec 2014
Posts: 388
Location: Russian Federation
Concentration: General Management, Economics
GMAT 1: 640 Q44 V33
WE: Sales (Telecommunications)
Followers: 0

Kudos [?]: 79 [0], given: 349

Re: In clinical trials of new medicines, half of the subjects receive the [#permalink]

### Show Tags

11 Dec 2014, 04:41
Choice A is correct. The question states " that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested". If " subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug" then initial condition is violated
_________________

"Are you gangsters?" - "No we are Russians!"

Manager
Joined: 05 Aug 2013
Posts: 91
Location: India
WE: Information Technology (Computer Software)
Followers: 2

Kudos [?]: 51 [0], given: 253

Re: In clinical trials of new medicines, half of the subjects receive the [#permalink]

### Show Tags

11 Dec 2014, 12:21
ajaym28 wrote:
In clinical trials of new medicines, half of the subjects receive the drug being tested and half receive a physiologically inert substance—a placebo. Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. However, this intention is frequently frustrated because______
Which one of the following, if true, most appropriately completes the explanation?
(A) often the subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug
(B) subjects who believe they are receiving the drug being tested often display improvements in their conditions regardless of whether what is administered to them is physiologically active or not
(C) in general, when the trial is intended to establish the experimental drug’s safety rather than its effectiveness, all of the subjects are healthy
(D) when a trial runs a long time, few of the experimenters will work on it from inception to conclusion
(E) the people who are subjects for clinical trials must, by law, be volunteers and must be informed of the possibility that they will receive a placebo

Can you please post OE for this question??
Manager
Joined: 23 Oct 2014
Posts: 109
Concentration: Marketing
GMAT 1: Q48 V25
Followers: 3

Kudos [?]: 48 [1] , given: 66

Re: In clinical trials of new medicines, half of the subjects receive the [#permalink]

### Show Tags

11 Dec 2014, 19:10
1
KUDOS
In clinical trials of new medicines, half of the subjects receive the drug being tested and half receive a physiologically inert substance—a placebo. Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. However, this intention is frequently frustrated because______

Which one of the following, if true, most appropriately completes the explanation?

The clinical trials are designed so that no on will know which subject is given the actual drug. To complete the explanation you must find out how this design can be compromised. Essentially, find out what can alert either the subjects or the experimenters who has the real drug.

(A) often the subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug
Bingo. If the experimenter knows what the symptoms are and the subject is exhibiting the symptoms then the experimenter will know that this subject has the real drug.

(B) subjects who believe they are receiving the drug being tested often display improvements in their conditions regardless of whether what is administered to them is physiologically active or not
This actually will enforce the design. If everyone, including the subjects with the placebo, has the same results then the design holds true. There is no way to figure out who has the real drug or who has the placebo.

(C) in general, when the trial is intended to establish the experimental drug’s safety rather than its effectiveness, all of the subjects are healthy
This is irrelevant. The trial's intent does nothing to compromise the design of the trial.

(D) when a trial runs a long time, few of the experimenters will work on it from inception to conclusion
This does not compromise the design of the trial.

(E) the people who are subjects for clinical trials must, by law, be volunteers and must be informed of the possibility that they will receive a placebo
Whether or the subject is a volunteer does not compromise the design of the trial.
GMAT Club Legend
Joined: 01 Oct 2013
Posts: 10543
Followers: 920

Kudos [?]: 204 [0], given: 0

Re: In clinical trials of new medicines, half of the subjects [#permalink]

### Show Tags

12 Feb 2016, 23:26
Hello from the GMAT Club VerbalBot!

Thanks to another GMAT Club member, I have just discovered this valuable topic, yet it had no discussion for over a year. I am now bumping it up - doing my job. I think you may find it valuable (esp those replies with Kudos).

Want to see all other topics I dig out? Follow me (click follow button on profile). You will receive a summary of all topics I bump in your profile area as well as via email.
Re: In clinical trials of new medicines, half of the subjects   [#permalink] 12 Feb 2016, 23:26
Similar topics Replies Last post
Similar
Topics:
A journalist discovered that drugs whose clinical trials are financed 2 26 Aug 2015, 08:52
In clinical trials of new medicines, half of the subjects receive the 0 11 Dec 2014, 19:19
33 Editorial: In a compelling preponderance of clinical trials, 29 01 Nov 2013, 12:23
The proposal to extend clinical trials, which are routinely 3 04 Jun 2010, 04:35
The proposal to extend clinical trials, which are routinely 15 06 Apr 2007, 01:58
Display posts from previous: Sort by